BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27545002)

  • 1. Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients.
    Yamaguchi K; Urakami K; Nagashima T; Shimoda Y; Ohnami S; Ohnami S; Ohshima K; Mochizuki T; Hatakeyama K; Serizawa M; Akiyama Y; Maruyama K; Katagiri H; Ishida Y; Takahashi K; Nishimura S; Terashima M; Kawamura T; Kinugasa Y; Yamakawa Y; Onitsuka T; Ohde Y; Sugino T; Ito I; Matsubayashi H; Horiuchi Y; Mizuguchi M; Yamazaki M; Inoue K; Wakamatsu K; Sugiyama M; Uesaka K; Kusuhara M
    Biomed Res; 2016; 37(4):259-64. PubMed ID: 27545002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation.
    Yamazaki F; Shima H; Osumi T; Narumi S; Kuroda T; Shimada H
    J Pediatr Hematol Oncol; 2018 Apr; 40(3):e195-e197. PubMed ID: 28902083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 germline mutations in adult patients with adrenocortical carcinoma.
    Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
    de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
    Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
    Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
    Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
    Id Said B; Kim H; Tran J; Novokmet A; Malkin D
    Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
    Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
    Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline TP53 variants and susceptibility to osteosarcoma.
    Mirabello L; Yeager M; Mai PL; Gastier-Foster JM; Gorlick R; Khanna C; Patiño-Garcia A; Sierrasesúmaga L; Lecanda F; Andrulis IL; Wunder JS; Gokgoz N; Barkauskas DA; Zhang X; Vogt A; Jones K; Boland JF; Chanock SJ; Savage SA
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25896519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of de novo mutations in Li-Fraumeni syndrome.
    Gonzalez KD; Buzin CH; Noltner KA; Gu D; Li W; Malkin D; Sommer SS
    J Med Genet; 2009 Oct; 46(10):689-93. PubMed ID: 19556618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
    Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
    Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of germline TP53 mutations and history of Li-Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: a population-based survey.
    Magnusson S; Gisselsson D; Wiebe T; Kristoffersson U; Borg Å; Olsson H
    Pediatr Blood Cancer; 2012 Nov; 59(5):846-53. PubMed ID: 22653678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
    Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE
    Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.